New targeted therapy significantly extends survival in pancreatic cancer

Vidcast:  https://www.instagram.com/p/DbOnPygOPyU/One of the most dramatic studies presented this week at the American Society of Clinical Oncology meeting involved pancreatic cancer—one of the deadliest forms of cancer, where treatment options are extremely limited after the disease progresses.Researchers reported results from a Phase 3 clinical trial of an experimental oral drug called daraxonrasib. Patients receiving the new treatment lived a median of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy—nearly doubling overall survival. The drug also delayed cancer progression while producing fewer serious side effects than chemotherapy.Experts called these findings potentially practice-changing, saying they could establish a new standard second-line treatment for metastatic pancreatic cancer if regulatory approval follows.References for this report are available on my website.#PancreaticCancer #CancerResearch #ClinicalTrials #ASCO #MedicalBreakthrough